1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks

 
• By Jung Won Shin

The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector. 

biotech
Roundup Of Korean Bioventure Developments • Source: Shutterstock

The hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with progress in original R&D activities notable across the board.

Among the major positives, an independent data monitoring committee (IDMC) has recommended the continuation of a Phase IIa trial for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

A VC Perspective On Korean Bioventures: New Catalysts Needed To Jumpstart Activity

 
• By Jung Won Shin

Stonebridge Ventures’ managing director Hyun-Ki Kim talks to Scrip on factors constraining the recovery of VC funding in Korean bioventures and its investment considerations, strategies and priorities.

Korean Firms Build RPT Strategies With Eye On Conditional Approvals

 
• By Jung Won Shin

Scrip takes a look at the "burgeoning" South Korea radiopharmaceuticals sector, where a handful of pioneering domestic companies are racing to advance their pipelines, with prostate cancer a strong early focus.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.

Korea Q2 Roundup: Global Sales, License Income Boost Yuhan, GC

 
• By Jung Won Shin

Yuhan and GC Biopharma’s performances stood out among South Korean companies reporting Q2 results, boosted by license income, strong global growth and exports, while many others reported generally weaker figures.

More from Focus On Asia

Chinese Cell And Gene Therapy Developers Ride Funding Spree

 
• By Dexter Jie Yan

Suzhou-based Accuredit Therapeutics led the pack of recent China financings with a $75m series A. Other major funding rounds in the country backed by venture capital and private equity firms included Beijing GRIT Biotechnology's $53.5m series C.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.

GLP-1s: Lilly, Novo Gallop In India, Generic Firms Gear ‘To Finish The Race’

 
• By Anju Ghangurde

Leaders from Eli Lilly, Novo Nordisk, Biocon, Dr Reddy’s and Levim discuss the huge India market potential for GLP-1s. Executives from the Indian firms also outlined efforts to build supply chain stability and cost-efficiency for products like semaglutide.